DK3377516T3 - Sammensætning til behandling af cancer - Google Patents

Sammensætning til behandling af cancer Download PDF

Info

Publication number: DK3377516T3
Authority: DK; Denmark
Prior art keywords: cancer; treatment; composition
Prior art date: 2015-11-20

Application number

DK16867262.4T

Other languages

English (en)

Inventor

David A Scheinberg

Original Assignee

Memorial Sloan Kettering Cancer Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-20

Filing date

2016-11-18

Publication date

2022-09-19

2016-11-18 Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center

2022-09-19 Application granted granted Critical

2022-09-19 Publication of DK3377516T3 publication Critical patent/DK3377516T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001141—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK16867262.4T 2015-11-20 2016-11-18 Sammensætning til behandling af cancer DK3377516T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562258134P	2015-11-20	2015-11-20
PCT/US2016/062865 WO2017087857A1 (en)	2015-11-20	2016-11-18	Methods and compositions for treating cancer

Publications (1)

Publication Number	Publication Date
DK3377516T3 true DK3377516T3 (da)	2022-09-19

Family

ID=58717878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16867262.4T DK3377516T3 (da)	2015-11-20	2016-11-18	Sammensætning til behandling af cancer

Country Status (19)

Country	Link
US (1)	US11033613B2 (da)
EP (2)	EP4130026A1 (da)
JP (3)	JP6991969B2 (da)
KR (1)	KR20180094922A (da)
CN (4)	CN115920017A (da)
AU (2)	AU2016356708B2 (da)
CA (1)	CA3005896A1 (da)
DK (1)	DK3377516T3 (da)
ES (1)	ES2926386T3 (da)
HR (1)	HRP20220994T1 (da)
HU (1)	HUE059694T2 (da)
LT (1)	LT3377516T (da)
MA (1)	MA43283B1 (da)
MD (1)	MD3377516T2 (da)
PL (1)	PL3377516T3 (da)
PT (1)	PT3377516T (da)
RS (1)	RS63561B1 (da)
SI (1)	SI3377516T1 (da)
WO (1)	WO2017087857A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10441654B2 (en)	2014-01-24	2019-10-15	Children's Hospital Of Eastern Ontario Research Institute Inc.	SMC combination therapy for the treatment of cancer
CN115920017A (zh)	2015-11-20	2023-04-07	纪念斯隆凯特林癌症中心	用于治疗癌症的方法和组合物
JP7071288B2 (ja)	2016-05-18	2022-05-18	キューバイオファーマ，インコーポレイテッド	Ｔ細胞調節多量体ポリペプチド及びその使用方法
US11472856B2 (en)	2016-06-13	2022-10-18	Torque Therapeutics, Inc.	Methods and compositions for promoting immune cell function
KR20190082850A (ko)	2016-11-30	2019-07-10	어드박시스, 인크.	반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
MX2019007611A (es)	2016-12-22	2020-07-29	Cue Biopharma Inc	Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
US11851471B2 (en)	2017-01-09	2023-12-26	Cue Biopharma, Inc.	T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018170168A1 (en)	2017-03-15	2018-09-20	Cue Biopharma, Inc.	Methods for modulating an immune response
WO2019006401A2 (en) *	2017-06-30	2019-01-03	Advaxis, Inc.	LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF
EP3678701A4 (en)	2017-09-05	2021-12-01	Torque Therapeutics, Inc.	THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF
MX2020004829A (es) *	2017-11-08	2020-11-11	Advaxis Inc	Péptidos heteroclíticos inmunogénicos de proteínas asociadas al cáncer y métodos de uso de los mismos.
CN111886241A (zh)	2018-01-09	2020-11-03	库尔生物制药有限公司	多聚体t细胞调节多肽及其使用方法
US12018045B2 (en)	2018-03-06	2024-06-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	17-beta-hydroxywithanolides and use thereof in treating cancer
TWI851607B (zh) *	2018-10-05	2024-08-11	日商癌免疫研究所股份有限公司	良性腫瘤之預防或治療藥
JP7549579B2 (ja) *	2018-12-19	2024-09-11	キューバイオファーマ，インコーポレイテッド	多量体ｔ細胞調節ポリペプチド及びその使用方法
EP3952908A4 (en) *	2019-04-10	2023-01-11	SLSG Limited LLC	MULTIVALENT THERAPEUTIC COMPOSITION AND METHODS OF USE FOR TREATING WT1 POSITIVE EXPRESSION CANCERS
TW202129013A (zh) *	2019-11-12	2021-08-01	美商方得生醫療公司	偵測編碼新生抗原之融合基因之方法
EP4085130A4 (en)	2019-12-31	2024-04-10	Elixirgen Therapeutics, Inc.	TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES
EP4132490A4 (en) *	2020-04-07	2024-04-24	Metanoi Therapeutics, Inc.	ETHANOLAMINE FORMULATION FOR THE TREATMENT OF EPITHELIAL OVARIAN CARCINOMA
CN116096405A (zh)	2020-05-12	2023-05-09	Cue生物制药股份有限公司	多聚体t细胞调节多肽及其使用方法
EP4211149A4 (en)	2020-09-09	2024-10-09	Cue Biopharma Inc	MHC CLASS II T-CELL MODULATING MULTIMER POLYPEPTIDES FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en)	1985-04-19	1998-11-17	The Wistar Institute	Method for generating an immunogenic T cell response protective against a virus
EP0573608A1 (en)	1991-02-07	1993-12-15	Molecumetics, Ltd.	Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
CA2168245A1 (en)	1993-07-29	1995-02-09	C. Anthony Hunt	Polynucleotide decoys that inhibit mhc-ii expression and uses thereof
US5643786A (en)	1995-01-27	1997-07-01	The United States Of America As Represented By The Department Of Health And Human Services	Method for isolating dendritic cells
PT1103564E (pt)	1998-07-31	2009-03-13	Int Inst Cancer Immunology Inc	Antigénios de cancro com base no produto do gene supressor de tumor wt1
TR200101482T2 (tr) *	1998-09-30	2002-01-21	Corixa Corporation	WT1'e özgü imünoterapi için bileşimler
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en)	1998-09-30	2006-10-03	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en)	1998-09-30	2008-02-12	Corixa Corporation	Compositions and method for WT1 specific immunotherapy
US7144581B2 (en)	2000-10-09	2006-12-05	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en)	1998-09-30	2010-02-02	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en)	1998-09-30	2006-06-20	Corixa Corporation	Composition and methods for WTI specific immunotherapy
US7901693B2 (en)	1998-09-30	2011-03-08	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
AU7859900A (en)	1999-10-04	2001-05-10	Corixa Corporation	Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en)	2000-02-22	2003-05-01	Alexander Gaiger	Compositions and methods for diagnosis and therapy of malignant mesothelioma
US7553494B2 (en)	2001-08-24	2009-06-30	Corixa Corporation	WT1 fusion proteins
US7420034B2 (en)	2002-06-12	2008-09-02	Dainippon Sumitomo Pharma Co., Ltd.	HLA-A24-restricted cancer antigen peptides
US10500257B2 (en)	2003-06-27	2019-12-10	International Institute Of Cancer Immunology, Inc.	Method of selecting WT1 vaccine adaptive patient
ATE540111T1 (de)	2003-11-05	2012-01-15	Int Inst Cancer Immunology Inc	Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist
US7488718B2 (en)	2003-12-01	2009-02-10	Sloan Kettering Institue For Cancer Research	Synthetic HLA binding peptide analogues and uses thereof
US20060127409A1 (en)	2003-12-01	2006-06-15	Scheinberg David A	Bcr-abl vaccines and methods of use thereof
US8765687B2 (en)	2005-10-17	2014-07-01	Sloan Kettering Institute For Cancer Research	WT1 HLA class II-binding peptides and compositions and methods comprising same
DE102006014261A1 (de)	2006-03-28	2007-10-04	Dr.Ing.H.C. F. Porsche Ag	Luftleitvorrichtung für ein Fahrzeug
ES2591029T3 (es)	2006-04-10	2016-11-24	Sloan Kettering Institute For Cancer Research	Péptidos WT-1 inmunogénicos y métodos para su uso
CA2881594C (en)	2007-12-05	2016-04-12	International Institute Of Cancer Immunology, Inc.	Cancer vaccine composition
US20110136141A1 (en)	2009-12-03	2011-06-09	Abbott Laboratories	Peptide reagents and method for inhibiting autoantibody antigen binding
US20150104413A1 (en) *	2012-01-13	2015-04-16	Memorial Sloan Kettering Cancer Center	Immunogenic wt-1 peptides and methods of use thereof
EP3769782A1 (en)	2013-01-15	2021-01-27	Memorial Sloan Kettering Cancer Center	Immunogenic wt-1 peptides and methods of use thereof
CN103961702B (zh) *	2013-02-05	2019-04-09	日东电工株式会社	粘膜给予用wt1肽癌症疫苗组合物
CN114225019A (zh) *	2013-03-15	2022-03-25	宾夕法尼亚大学理事会	癌疫苗及使用其的治疗方法
US20150118222A1 (en)	2013-10-25	2015-04-30	Pharmacyclics, Inc.	Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
EP4461372A2 (en)	2013-11-05	2024-11-13	Cognate Bioservices, Inc.	Combinations of checkpoint inhibitors and therapeutics to treat cancer
EP4070818A3 (en) *	2014-01-06	2023-01-11	The Trustees of the University of Pennsylvania	Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
JP2017510297A (ja)	2014-03-17	2017-04-13	タピミューンインコーポレイテッド	核酸分子ワクチン組成物およびその使用
WO2016186177A1 (ja)	2015-05-20	2016-11-24	大日本住友製薬株式会社	Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
CN115920017A (zh)	2015-11-20	2023-04-07	纪念斯隆凯特林癌症中心	用于治疗癌症的方法和组合物

2016
- 2016-11-18 CN CN202210863749.3A patent/CN115920017A/zh active Pending
- 2016-11-18 SI SI201631597T patent/SI3377516T1/sl unknown
- 2016-11-18 JP JP2018526090A patent/JP6991969B2/ja active Active
- 2016-11-18 HR HRP20220994TT patent/HRP20220994T1/hr unknown
- 2016-11-18 MA MA43283A patent/MA43283B1/fr unknown
- 2016-11-18 LT LTEPPCT/US2016/062865T patent/LT3377516T/lt unknown
- 2016-11-18 KR KR1020187017393A patent/KR20180094922A/ko not_active Application Discontinuation
- 2016-11-18 PT PT168672624T patent/PT3377516T/pt unknown
- 2016-11-18 WO PCT/US2016/062865 patent/WO2017087857A1/en active Application Filing
- 2016-11-18 EP EP22175680.2A patent/EP4130026A1/en active Pending
- 2016-11-18 HU HUE16867262A patent/HUE059694T2/hu unknown
- 2016-11-18 MD MDE20180934T patent/MD3377516T2/ro unknown
- 2016-11-18 ES ES16867262T patent/ES2926386T3/es active Active
- 2016-11-18 CN CN202210863762.9A patent/CN116327903A/zh active Pending
- 2016-11-18 RS RS20220828A patent/RS63561B1/sr unknown
- 2016-11-18 EP EP16867262.4A patent/EP3377516B1/en active Active
- 2016-11-18 PL PL16867262.4T patent/PL3377516T3/pl unknown
- 2016-11-18 AU AU2016356708A patent/AU2016356708B2/en active Active
- 2016-11-18 CA CA3005896A patent/CA3005896A1/en active Pending
- 2016-11-18 DK DK16867262.4T patent/DK3377516T3/da active
- 2016-11-18 CN CN201680077975.1A patent/CN108431022B/zh active Active
- 2016-11-18 US US15/777,514 patent/US11033613B2/en active Active
- 2016-11-18 CN CN202210862167.3A patent/CN116327902A/zh active Pending
2021
- 2021-12-08 JP JP2021198966A patent/JP2022033926A/ja active Pending
2022
- 2022-05-03 AU AU2022202973A patent/AU2022202973A1/en active Pending
2023
- 2023-12-27 JP JP2023220529A patent/JP2024041809A/ja active Pending

Also Published As

Publication number	Publication date
WO2017087857A1 (en)	2017-05-26
JP6991969B2 (ja)	2022-03-03
MA43283A (fr)	2018-09-26
LT3377516T (lt)	2022-09-26
PL3377516T3 (pl)	2022-10-10
HRP20220994T1 (hr)	2022-11-11
PT3377516T (pt)	2022-09-23
CN108431022A (zh)	2018-08-21
CN116327903A (zh)	2023-06-27
EP3377516A1 (en)	2018-09-26
CN115920017A (zh)	2023-04-07
AU2016356708B2 (en)	2022-02-03
EP4130026A1 (en)	2023-02-08
ES2926386T3 (es)	2022-10-25
SI3377516T1 (sl)	2023-01-31
MD3377516T2 (ro)	2022-10-31
JP2018538265A (ja)	2018-12-27
US11033613B2 (en)	2021-06-15
MA43283B1 (fr)	2022-08-31
EP3377516A4 (en)	2019-06-26
US20180339030A1 (en)	2018-11-29
CN116327902A (zh)	2023-06-27
AU2022202973A1 (en)	2022-05-26
EP3377516B1 (en)	2022-06-15
RS63561B1 (sr)	2022-10-31
CA3005896A1 (en)	2017-05-26
KR20180094922A (ko)	2018-08-24
AU2016356708A1 (en)	2018-07-05
HUE059694T2 (hu)	2022-12-28
JP2022033926A (ja)	2022-03-02
CN108431022B (zh)	2022-08-09
JP2024041809A (ja)	2024-03-27

Publication	Publication Date	Title
DK3377516T3 (da)	2022-09-19	Sammensætning til behandling af cancer
DK3431105T3 (da)	2020-03-09	Medicinsk sammensætning til behandling af cancer
DK3288581T3 (da)	2021-01-11	Fremgangsmåde til behandling af cancer
DK3166976T3 (da)	2022-04-11	Anti-pd-l1-kombinationer til behandling af tumorer
DK3326641T3 (da)	2019-09-30	Rna-holdig sammensætning til behandling af tumorsygdomme
DK3189082T3 (da)	2020-09-21	Anti-pd-l1-konjugater til behandling af tumorer
DK3286311T3 (da)	2021-05-17	Fremgangsmåde til behandling af maligniteter
DK3134530T3 (da)	2019-09-09	Behandling af hyperbilirubinæmi
DK3594238T3 (da)	2021-04-19	Antistofsammensætninger til tumorbehandling
DK3439635T3 (da)	2021-03-08	Formuleringer til behandling af fast tumor
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3261726T3 (da)	2019-06-24	Sammensætning til behandling af acne
DK3148529T3 (da)	2021-12-13	Forbindelser til behandling af hjernecancer
DK3277270T3 (da)	2021-12-06	Sammensætninger og fremgangsmåder til behandling af anæmi
DK3362066T3 (da)	2021-11-22	Kombinationsterapi til behandling af maligniteter
DK3458052T3 (da)	2020-02-03	Kombinationsbehandling af cancer
DK3200815T3 (da)	2021-05-10	Fremgangsmåder og sammensætninger til behandling af cancer
DK3186244T3 (da)	2020-07-13	Dioxolananaloger af uridin til behandling af cancer
DK3143026T3 (da)	2024-09-30	Forbindelser og sammensætninger til induktion af chondrogenese
DK3371165T3 (da)	2022-05-02	Btk-inhibitor til anvendelse til behandling af kræft
DK3353177T3 (da)	2020-08-24	Tricykliske heterocykler til behandling af cancer
DK3318115T3 (da)	2020-04-14	Maskine til behandling af svinegylle
DK3307267T3 (da)	2019-07-01	Behandling af multipel sklerose
DK3213752T3 (da)	2019-09-02	Sammensætning til behandling af cancerstamceller
DK3468604T3 (da)	2021-04-19	Farmaceutiske kombinationer til behandling af cancer